The activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is key for antitumor immunity. However, the development of STING agonist-based strategies in cancer has so far encountered limitations such as incomplete tumor regression or adverse effects derived from chronic activation.